Key result
The management of venous thromboembolism in supportive and palliative care remains challenging, requiring individualized approaches and consideration of new oral anticoagulants.
This review emphasizes the importance of individualized VTE management, including the use of new oral anticoagulants, for patients in supportive and palliative care settings where standard clinical trial evidence is often lacking.
Answers are grounded in this paper and cite their sources.
Supports individualized palliative VTE strategies; leaves open optimal NOAC use pending dedicated trials.
PURPOSE OF REVIEW: Venous thromboembolism (VTE) comprising deep vein thrombosis and pulmonary embolus, confers a significant symptom burden in the supportive care setting, and yet is often unrecognized. Its management remains challenging because the clinical trials informing practice recruited patients that are largely unrepresentative of the advanced disease populations. RECENT FINDINGS: Recent years have seen several developments in the management of VTE including new oral anticoagulants, an appreciation of the patient's experience of VTE, and the importance of considering other comorbidities in ensuring an individualized approach to VTE treatment. SUMMARY: This study reviews the challenges of VTE management within supportive and palliative care, the new oral anticoagulants and the management of VTE in cases in which the evidence is lacking.
No takes yet. Share an insight, caveat, or question.
A 2016 study conducted a review in Venous thromboembolism (VTE). New oral anticoagulants and individualized VTE management was evaluated. The management of venous thromboembolism in supportive and palliative care remains challenging, requiring individualized approaches and consideration of new oral anticoagulants.
Synapse has enriched 10 related papers. Consider them for comparative context: